WhiteHawk Therapeutics Q4运营亏损2488.7万美元,远逊于IBES预估的15.4万美元

美股速递
Yesterday

WhiteHawk Therapeutics, Inc.最新公布的第四季度财务数据显示,其运营状况令人担忧。报告期内,公司运营收入为亏损2488.7万美元,这一数字与市场研究机构IBES此前预估的15.4万美元盈利形成了巨大反差,凸显出公司在核心业务上的盈利能力面临严峻挑战。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10